Compare · ABBV vs ASND
ABBV vs ASND
Side-by-side comparison of AbbVie Inc. (ABBV) and Ascendis Pharma A/S (ASND): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ASND operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $406.38B, about 28.8x ASND ($14.13B).
- Over the past year, ABBV is up 27.9% and ASND is up 35.9% - ASND leads by 8.0 points.
- ABBV has been more active in the news (14 items in the past 4 weeks vs 11 for ASND).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Ascendis Pharma A/S
- Price
- $234.88+2.11%
- $238.77+4.68%
- Market cap
- $406.38B
- $14.13B
- 1M return
- +9.46%
- -3.51%
- 1Y return
- +27.86%
- +35.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2015
- News (4w)
- 14
- 11
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
- AbbVie Declares Quarterly Dividend
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- FDA Approval for SKYRIZI issued to ABBVIE INC
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest ASND
- SEC Form 6-K filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
- Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
- SEC Form 6-K filed by Ascendis Pharma A/S
- 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
- EVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)
- Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)
- EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)